View : 351 Download: 0

Full metadata record

DC Field Value Language
dc.contributor.author박경란-
dc.date.accessioned2017-03-01T01:03:47Z-
dc.date.available2017-03-01T01:03:47Z-
dc.date.issued2017-
dc.identifier.issn1598-2998-
dc.identifier.issn2005-9256-
dc.identifier.otherOAK-20139-
dc.identifier.urihttp://dspace.ewha.ac.kr/handle/2015.oak/234633-
dc.description.abstractPurpose The The purpose of this study was to evaluate the benefits of adjuvant treatment for curatively resected thoracic esophageal squamous cell carcinoma (ESCC) and determine the optimal adjuvant treatments. Materials and Methods One hundred ninety-five patients who underwent a curative resection for thoracic ESCC between 1994 and 2014 were reviewed retrospectively. Postoperatively, the patients received no adjuvant treatment (no-adjuvant group, n=68), adjuvant chemotherapy (AC group, n=62), radiotherapy (RT group, n=41), or chemoradiotherapy (CRT group, n=24). Chemotherapy comprised cisplatin and 5-fluorouracil administration every 3 weeks. The median RT dose was 45.0 Gy (range, 34.8 to 59.4 Gy). The overall survival (OS), disease free survival (DFS), locoregional recurrence (LRR), and distant metastasis (DM) rates were estimated. Results At a median follow-up duration of 42.2 months (range, 6.3 to 215.2 months), the 5-year OS and DFS were 37.6% and 31.4%, respectively. After adjusting for other clinicopathologic variables, the AC and CRT groups had a significantly better OS and DFS compared to the no-adjuvant group (p < 0.05). The LRR rate was significantly lower in the RT and CRT groups than in the no-adjuvant group (p < 0.05), whereas no significant difference was observed in the AC group. In the no-adjuvant and AC groups, 25% of patients received high-dose salvage RT due to LRR. The DM rates were similar. The anastomotic stenosis and leakage were similar in the treatment groups. Conclusion Adjuvant treatment might prolong survival after an ESCC resection, and RT contributes to a reduction of the LRR. Overall, the risks and benefits should be weighed properly when selecting the optimal adjuvant treatment.-
dc.languageEnglish-
dc.publisherKOREAN CANCER ASSOCIATION-
dc.subjectEsophageal neoplasms-
dc.subjectSquamous cell carcinoma-
dc.subjectDrug therapy-
dc.subjectRadiotherapy-
dc.titleOptimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective-
dc.typeArticle-
dc.relation.issue1-
dc.relation.volume49-
dc.relation.indexSCIE-
dc.relation.indexSCOPUS-
dc.relation.indexKCI-
dc.relation.startpage168-
dc.relation.lastpage177-
dc.relation.journaltitleCANCER RESEARCH AND TREATMENT-
dc.identifier.doi10.4143/crt.2016.142-
dc.identifier.wosidWOS:000391899800018-
dc.identifier.scopusid2-s2.0-85010338484-
dc.author.googleKim, Kyung Hwan-
dc.author.googleChang, Jee Suk-
dc.author.googleCha, Ji Hye-
dc.author.googleLee, Lk Jae-
dc.author.googleKim, Dae Joon-
dc.author.googleCho, Byoung Chul-
dc.author.googlePark, Kyung Ran-
dc.author.googleLee, Chang Geol-
dc.contributor.scopusid박경란(14040340300)-
dc.date.modifydate20180104081001-
Appears in Collections:
의료원 > 의료원 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE